Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
Angiotensin-Converting Enzyme 2
/ genetics
Animals
Antiviral Agents
/ pharmacology
Aurintricarboxylic Acid
/ pharmacology
COVID-19
/ virology
Chlorocebus aethiops
Drug Discovery
Ellagic Acid
/ pharmacology
Heparin
/ pharmacology
High-Throughput Screening Assays
Humans
Inhibitory Concentration 50
Molecular Docking Simulation
Protein Domains
/ genetics
Recombinant Proteins
/ genetics
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ antagonists & inhibitors
Vero Cells
Virus Internalization
/ drug effects
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
angiotensin-converting enzyme 2 (ACE2), high-throughput screening
drug repurposing
receptor binding domain (RBD)
small molecule inhibitors (SMIs)
spike protein
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
27 May 2021
27 May 2021
Historique:
received:
02
05
2021
revised:
20
05
2021
accepted:
24
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
9
6
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) global pandemic. The first step of viral infection is cell attachment, which is mediated by the binding of the SARS-CoV-2 receptor binding domain (RBD), part of the virus spike protein, to human angiotensin-converting enzyme 2 (ACE2). Therefore, drug repurposing to discover RBD-ACE2 binding inhibitors may provide a rapid and safe approach for COVID-19 therapy. Here, we describe the development of an in vitro RBD-ACE2 binding assay and its application to identify inhibitors of the interaction of the SARS-CoV-2 RBD to ACE2 by the high-throughput screening of two compound libraries (LOPAC
Identifiants
pubmed: 34072087
pii: molecules26113213
doi: 10.3390/molecules26113213
pmc: PMC8198929
pii:
doi:
Substances chimiques
Antiviral Agents
0
Recombinant Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Ellagic Acid
19YRN3ZS9P
Aurintricarboxylic Acid
4431-00-9
Heparin
9005-49-6
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : This work was supported by the Israel Institute for Biological Chemical and Environmental Sciences
ID : SB182
Références
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
J Virol. 2007 Mar;81(6):3027-32
pubmed: 17192307
Front Microbiol. 2019 Apr 12;10:718
pubmed: 31031722
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Biochem Biophys Res Commun. 2004 Aug 6;320(4):1199-203
pubmed: 15249217
Molecules. 2020 Dec 24;26(1):
pubmed: 33374387
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7
pubmed: 21624888
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:465-493
pubmed: 32574109
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):85-98
pubmed: 8118391
Glycobiology. 1998 Feb;8(2):131-7
pubmed: 9451022
Antiviral Res. 2009 Feb;81(2):123-31
pubmed: 19014974
Environ Int. 2021 Feb;147:106361
pubmed: 33401173
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
J Biol Chem. 2003 Oct 24;278(43):41734-41
pubmed: 12888560
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Recent Pat Inflamm Allergy Drug Discov. 2018;12(1):24-38
pubmed: 29473532
Front Pharmacol. 2021 Mar 04;12:634176
pubmed: 33897423
Antiviral Res. 2017 Apr;140:13-17
pubmed: 28063994
Altern Med Rev. 2008 Jun;13(2):128-44
pubmed: 18590349
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Commun. 2020 Sep 11;11(1):4541
pubmed: 32917884
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Adv Exp Med Biol. 2016;928:473-479
pubmed: 27671829
Viruses. 2018 Mar 27;10(4):
pubmed: 29584652
Nat Commun. 2021 Feb 11;12(1):944
pubmed: 33574228
Sci Rep. 2021 Jan 8;11(1):234
pubmed: 33420186
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Oral Dis. 2018 Mar;24(1-2):249-252
pubmed: 29480632
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2602-7
pubmed: 17293454
Curr Pharm Des. 2016;22(10):1350-60
pubmed: 26806345
Planta Med. 2018 Oct;84(15):1068-1093
pubmed: 29847844
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Viruses. 2020 Jun 30;12(7):
pubmed: 32629804
Curr Pharm Des. 2018;24(2):106-122
pubmed: 29141541
J Biomol Struct Dyn. 2020 Jul 20;:1-23
pubmed: 32686993
Front Immunol. 2020 Jul 10;11:1664
pubmed: 32754161
Biomed Pharmacother. 2018 Feb;98:29-35
pubmed: 29241072
Semin Cancer Biol. 2016 Oct;40-41:48-81
pubmed: 26853158
Angew Chem Int Ed Engl. 2021 Apr 26;60(18):10273-10278
pubmed: 33684258
Neurochem Res. 2016 Jun;41(6):1219-28
pubmed: 26846140
J Chem Inf Model. 2015 Nov 23;55(11):2324-37
pubmed: 26479676
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
J Virol. 2014 Nov;88(22):13221-30
pubmed: 25187545
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Biochem Pharmacol. 1995 Jan 31;49(3):305-13
pubmed: 7857317
Med Res Rev. 2011 Jan;31(1):118-60
pubmed: 19844936
Cell Mol Neurobiol. 2012 Apr;32(3):319-36
pubmed: 22198555
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antiviral Res. 2020 Sep;181:104873
pubmed: 32653452
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell Discov. 2020 Jul 24;6:50
pubmed: 32714563
Breast Cancer. 2018 Sep;25(5):517-528
pubmed: 29725861
Crit Rev Food Sci Nutr. 2004;44(1):1-17
pubmed: 15077879
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Nat Commun. 2020 Dec 16;11(1):6402
pubmed: 33328475